RxDoctor Payments Data

Duane Shroyer, MD

Internal Medicine · Birmingham, ALNPI 1467426346

Payments from drug & device makers

$1,403in general payments, 2019–2025

Across 93 payments — averaging $15.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$229
  • AstraZeneca$195
  • Pfizer$175
  • GSK$121
  • Dexcom, Inc.$107
  • Amgen$103
  • plus $475 from 14 others

What the payments were for

  • Food & beverage$1,397100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,403 in reported general payments places this provider in the 65th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$186,395
Medicare patients
210
Services billed
10,497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$151,696
OzempicSemaglutide142$150,421
JanuviaSitagliptin Phosphate140$127,840
JardianceEmpagliflozin119$108,507
MounjaroTirzepatide67$78,834
MyrbetriqMirabegron100$56,448
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$45,314
TrulicityDulaglutide40$38,129
XareltoRivaroxaban31$25,907
FarxigaDapagliflozin Propanediol17$20,522
ViberziEluxadoline13$20,176
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog33$19,235
Breo ElliptaFluticasone/Vilanterol32$16,598
GlyxambiEmpagliflozin/Linagliptin14$12,933
Tresiba Flextouch U-200Insulin Degludec19$12,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$175$151,696161 claims
Novo NordiskOzempic$85$150,421142 claims
Lilly USA, LLCMounjaro, Trulicity$44$116,964107 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$121$67,47798 claims
Astellas Pharma US IncMyrbetriq$60$56,448100 claims
AstraZenecaFarxiga, Breztri Aerosphere$195$28,34930 claims
AbbVieViberzi, Synthroid$229$27,22496 claims
Johnson & JohnsonXarelto$25$25,90731 claims
NovartisEntresto$50$9,78614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →